Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Beyer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Antje Rottmann

Andrea Rotgeri

Jens Nagel

Jürgen Klar

Nico Bräuer

Adam James Davenport

Oliver Martin Fischer

Anne-Marie Godinho-Coelho

Ioana Neagoe

Horst Irlbacher

Andrea Wagenfeld

Hans-Christian Militzer

Benjamin Bader

Arwed Cleve

Marcus Koppitz

Orlin Petrov

Olaf Panknin

Holger Siebeneicher

Ulrike Fuhrmann

Antonius Ter Laak

Reinhard Nubbemeyer

Ildiko Terebesi

Holger Steuber

Stefan Pruehs

Hana Cernecka

Gunnar Garke

Juergen Klar

Michaele Peters

Carsten Moeller

Gernot Langer

Anja Schmidt

Marcus Schultze-Mosgau

Nico Braeuer

Margarete Brudny-Kloeppel

Rainer Hasselmann

Katrin Nowak-reppel

Frank Sacher

Nicole Schmidt

Sabine Pilari

Ondozabal Hideki Miyatake

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

1,3-thiazol-2-yl substituted benzamides

This invention concerns Selective Progesterone Receptor Modulators (SPRM) in a prodrug form as well as their application in therapy. (3&#x3b1;, 11&#x3b2;,17&#x3b2;)-1 1-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-diene-3,17-diol (Compound 1) is one of the invention prodrugs. 

Prodrugs of the selective progesterone receptor modulator (SPRM) (11.beta.,17.beta.)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl] -17-(pentafluoroethyl)estra-4,9-dien-3-one

The present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone compounds of general formula (I): in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of gynecological disorders, hyperproliferative disorders, metabolic disorders, or inflammatory disorders as a sole agent or in combination with other active ingredients.

[8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones

The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.

Progesterone receptor antagonists

Growing community of inventors

Berlin, Germany

Antje Rottmann